Uppsala, Sweden: Gyros AB has launched a new website to support its position as the leader in utilization of microfluidic technologies to miniaturize and automate immunoassays.

The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents.

Visitors new to Gyros can view scientists discussing their experiences when evaluating and implementing the Gyros immunoassay platform into their workflows. Presentations, made during recent user seminars, cover a wide range of applications used during discovery and development, through preclinical and clinical trials and in bioprocess development and production. Typical application examples include pharmacokinetic and pharmacodynamic analysis, biomarker monitoring and impurity testing.

Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers.

With a steadily increasing number of installations in major biopharmaceutical companies, CMOs and CROs, the new web structure will also facilitate addition of a User Support Zone. Users will have instant, round-the-clock access to frequently asked questions, technical tips and manuals, adding another tool to a comprehensive range of application, regulatory and service support.

Gyros has over 60 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe and is expanding its global reach through a network of distributors.

About Gyros AB

Gyros® is the world leader in automated micro-immunoassays for therapeutic protein development. Gyrolab®, the company’s automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry. https://www.gyros.com